Acadian Asset Management LLC Sells 31,065 Shares of Insulet Corporation $PODD

Acadian Asset Management LLC decreased its holdings in Insulet Corporation (NASDAQ:PODD) by 57.0% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 23,391 shares of the medical instruments supplier’s stock after selling 31,065 shares during the period. Acadian Asset Management LLC’s holdings in Insulet were worth $7,340,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently bought and sold shares of the company. Vanguard Group Inc. lifted its stake in shares of Insulet by 2.1% during the 1st quarter. Vanguard Group Inc. now owns 8,668,952 shares of the medical instruments supplier’s stock worth $2,276,553,000 after purchasing an additional 178,976 shares during the last quarter. American Century Companies Inc. raised its holdings in Insulet by 34.8% in the first quarter. American Century Companies Inc. now owns 1,152,606 shares of the medical instruments supplier’s stock worth $302,686,000 after purchasing an additional 297,734 shares in the last quarter. Groupama Asset Managment lifted its position in shares of Insulet by 0.4% during the first quarter. Groupama Asset Managment now owns 1,053,759 shares of the medical instruments supplier’s stock valued at $276,728,000 after buying an additional 3,759 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of Insulet by 4.2% during the first quarter. Charles Schwab Investment Management Inc. now owns 674,367 shares of the medical instruments supplier’s stock valued at $177,096,000 after buying an additional 27,408 shares during the last quarter. Finally, Federated Hermes Inc. boosted its holdings in shares of Insulet by 23.4% in the 1st quarter. Federated Hermes Inc. now owns 632,869 shares of the medical instruments supplier’s stock valued at $166,198,000 after buying an additional 120,197 shares in the last quarter.

Insider Activity

In other news, SVP Prem Singh sold 687 shares of Insulet stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $347.49, for a total value of $238,725.63. Following the sale, the senior vice president directly owned 3,456 shares of the company’s stock, valued at $1,200,925.44. The trade was a 16.58% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Laetitia Cousin sold 797 shares of the company’s stock in a transaction on Monday, September 8th. The stock was sold at an average price of $348.81, for a total transaction of $278,001.57. Following the sale, the senior vice president directly owned 3,890 shares of the company’s stock, valued at $1,356,870.90. The trade was a 17.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 0.39% of the company’s stock.

Insulet Trading Up 3.2%

Insulet stock opened at $336.84 on Thursday. The firm has a market cap of $23.70 billion, a PE ratio of 102.38, a P/E/G ratio of 2.64 and a beta of 1.39. Insulet Corporation has a 12 month low of $230.05 and a 12 month high of $353.50. The stock’s 50 day simple moving average is $324.17 and its two-hundred day simple moving average is $311.37. The company has a current ratio of 2.26, a quick ratio of 1.81 and a debt-to-equity ratio of 0.64.

Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $1.24 earnings per share for the quarter, topping analysts’ consensus estimates of $1.13 by $0.11. The business had revenue of $521.70 million during the quarter, compared to the consensus estimate of $678.70 million. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The company’s revenue was up 29.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.08 earnings per share. Insulet has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Analysts anticipate that Insulet Corporation will post 3.92 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on PODD shares. Truist Financial increased their target price on shares of Insulet from $365.00 to $390.00 and gave the company a “buy” rating in a research report on Friday, November 7th. JPMorgan Chase & Co. upped their price target on Insulet from $340.00 to $415.00 and gave the stock an “overweight” rating in a research report on Friday, September 12th. UBS Group raised their price objective on Insulet from $320.00 to $355.00 and gave the stock a “neutral” rating in a research report on Friday, November 7th. BTIG Research restated a “buy” rating and set a $370.00 target price on shares of Insulet in a research note on Thursday, November 6th. Finally, Stifel Nicolaus started coverage on Insulet in a research note on Tuesday, October 21st. They issued a “buy” rating and a $370.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $374.10.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.